Post by : Badri Ariffin

Abu Dhabi Biobank, a collaboration initiative led by the Department of Health – Abu Dhabi and M42, has entered into a partnership with global biopharmaceutical leader AstraZeneca to propel advancements in precision medicine and clinical research.

This collaboration merges Abu Dhabi Biobank's innovative biobanking, genomic capabilities, and population health metrics with AstraZeneca’s extensive expertise in critical therapy fields such as cardiovascular, renal, metabolic, respiratory, immunology, and oncology. The primary aim is to convert scientific research into health solutions.

Both organisations will jointly pursue various strategic focuses such as clinical development, precision medicine, and generating real-world evidence. Their efforts will enhance biomarker discovery, pharmacogenomics, and better patient stratification, enabling healthcare professionals to gain deeper insights into diseases and tailor treatments accordingly.

Additionally, this partnership will delve into health economics, regulatory science, and emerging domains like digital health and artificial intelligence. These initiatives are designed to fortify data-driven healthcare infrastructures and expedite the transition of research findings into clinical applications.

Albarah ElKhani, COO of Integrated Health Solutions at M42, expressed that the alliance signifies a mutual objective to redefine the future of medicine. He pointed out that blending comprehensive population data from Abu Dhabi Biobank with AstraZeneca’s scientific knowledge could unlock new avenues in disease prevention, diagnosis, and treatment, particularly for Middle Eastern demographics.

Sameh ElFangary, Country President for Gulf and Pakistan at AstraZeneca, emphasized that precision medicine should embody the diversity of populations worldwide. He mentioned that this collaboration will aid in the earlier identification of at-risk patients, especially in the context of rare and difficult-to-diagnose illnesses, contributing to the development of more tailored care plans.

This partnership signifies a key development in Abu Dhabi's ambition to establish itself as a leading center for biomedical research and life sciences innovation. By leveraging extensive population data and local insights, the collaboration seeks to hasten the journey from research discovery to regulatory endorsement and real-world application.

#Global News